Abstract: Evasion of apoptosis is a fundamental hallmark of cancer, often driven by the dysregulation of the BCL-2 family of proteins. In solid tumors and hematological malignancies, the overexpression of anti-apoptotic proteins such as MCL-1 contributes significantly to tumor progression and resistance to conventional therapies. S63845 is a highly specific and potent BH3-mimetic designed to selectively inhibit MCL-1. By mimicking the action of pro-apoptotic BH3-only proteins, S63845 disrupts the interaction between MCL-1 and pro-apoptotic effectors, thereby lowering the threshold for mitochondrial outer membrane permeabilization (MOMP) and triggering cell death. Current literature highlights S63845 as a promising therapeutic agent, demonstrating efficacy and tolerability across diverse cancer models, including solid tumors where MCL-1 is frequently amplified. This review synthesizes the pharmacological activity, molecular mechanisms, and future clinical perspectives of S63845 based on recent insights into mitochondrial apoptosis targeting.
1. Introduction
The evasion of programmed cell death, or apoptosis, is an established hallmark of cancer [1]. In mammalian cells, the intrinsic apoptotic pathway is primarily regulated at the mitochondria by the BCL-2 family of proteins, which includes both pro-apoptotic (e.g., BAX, BAK, BIM, PUMA) and anti-apoptotic (e.g., BCL-2, BCL-XL, MCL-1) members [1][2]. The delicate balance and interactions between these proteins set the threshold for mitochondrial outer membrane permeabilization (MOMP), a critical step that commits a cell to death [1].
In many cancers, including solid tumors, this apoptotic landscape is altered. The amplification or overexpression of anti-apoptotic genes, particularly BCL2L1 (encoding BCL-XL) and MCL1, is frequently observed and serves to suppress the pro-apoptotic effects of oncogenic transformation and genomic instability [1]. Overexpression of MCL-1, in particular, has been documented in numerous myeloid and solid tumors, such as breast tumors, and is often associated with poor clinical outcomes [1][2]. To exploit this cancer cell vulnerability, a new class of targeted drugs known as BH3-mimetics has been developed. Among these, S63845 has emerged as a highly potent and selective inhibitor of MCL-1, offering a novel therapeutic approach for MCL-1-dependent tumors [1][2].
2. Pharmacological Activity
S63845 has demonstrated significant pharmacological activity by effectively and safely targeting cancer cells that rely on MCL-1 for survival. Preclinical studies have shown that S63845 is tolerable and effective across diverse cancer models [1][2]. In the context of solid tumors, where MCL-1 is frequently amplified and acts as a major resistance factor, the pharmacological inhibition of MCL-1 by S63845 provides a critical mechanism to induce tumor regression [1].
Furthermore, S63845 exhibits the potential to overcome acquired resistance to other targeted therapies. For instance, resistance to the BCL-2 inhibitor venetoclax is often mediated by a compensatory increase in MCL-1 expression, which creates a bypass pathway for cancer cell survival [2]. By specifically neutralizing MCL-1, S63845 can break this resistance, making it a highly valuable pharmacological agent both as a monotherapy in MCL-1-driven cancers and in combination regimens [2].
3. Molecular Mechanism of Action
The molecular mechanism of S63845 is rooted in its function as a BH3-mimetic. Physiologically, BH3-only proteins (such as BIM, PUMA, and NOXA) initiate apoptosis by binding to the hydrophobic grooves of anti-apoptotic proteins, thereby releasing pro-apoptotic effectors like BAX and BAK to form pores in the mitochondrial membrane (MOMP) [1].
S63845 is designed to mimic the BH3 domain of these natural pro-apoptotic proteins. It binds directly to the canonical interaction site—the BH3-binding groove—of the anti-apoptotic protein MCL-1 [1]. By occupying this groove, S63845 competitively displaces pro-apoptotic proteins that were sequestered by MCL-1. This disruption neutralizes the anti-apoptotic function of MCL-1, shifting the cellular balance toward apoptosis and rapidly inducing MOMP and subsequent cell death in primed cancer cells [1][2].
4. Structure-Activity Relationship (SAR)
While early BH3-mimetics like ABT-737 and navitoclax (ABT-263) exhibited broad affinity for multiple anti-apoptotic proteins (BCL-2, BCL-XL, and BCL-W), they lacked efficacy against MCL-1 and caused on-target toxicities such as thrombocytopenia due to BCL-XL inhibition [1][2]. The structural development of S63845 by Servier represents a significant advancement in SAR within this drug class. S63845 was optimized to achieve the greatest specificity for MCL-1 over BCL-2 and BCL-XL [1]. This high selectivity ensures that S63845 tightly binds the unique structural conformation of the MCL-1 hydrophobic groove, maximizing on-target cancer cell killing while minimizing the adverse side effects associated with the cross-inhibition of other BCL-2 family members [1].
5. Current Limitations
Despite its promise, the clinical application of BH3-mimetics like S63845 faces several limitations. A primary concern is the emergence of acquired drug resistance. As observed with the BCL-2 inhibitor venetoclax, cancer cells can acquire de novo missense mutations within the BH3-binding pocket (e.g., G101V or D103Y in BCL-2) that impede drug binding while preserving the protein's anti-apoptotic function [1]. Similar mutational evasion could potentially arise in the MCL-1 binding groove following prolonged exposure to S63845.
Additionally, the apoptotic landscape of cancer is highly dynamic and heterogeneous. Single cancer cells can rapidly shift their apoptotic threshold in response to internal and external signals from the tumor microenvironment [1]. Furthermore, solid tumors often rely on a combination of anti-apoptotic proteins (e.g., co-amplification of BCL-XL and MCL-1) rather than a single dependency, meaning that inhibiting MCL-1 alone with S63845 might be insufficient to induce apoptosis in tumors with redundant survival pathways [1].
6. Future Perspectives
The future of S63845 and MCL-1 inhibition lies in rational combination therapies and precision medicine. Because solid tumors frequently exhibit complex apoptotic dependencies, combining S63845 with other targeted agents—such as BCL-2/BCL-XL inhibitors, kinase inhibitors, or conventional chemotherapies—holds great potential to synergistically increase apoptotic priming and overcome resistance [1][2].
To optimize these combinations, predictive diagnostic tools like dynamic BH3-profiling will be crucial. BH3-profiling measures the mitochondrial priming of primary cancer cells, allowing clinicians to functionally determine a tumor's specific anti-apoptotic dependencies before treatment [1]. As S63845 continues to undergo clinical trials, integrating such predictive biomarkers will help identify the specific solid tumor patient populations most likely to benefit from MCL-1 targeted therapy, ultimately maximizing therapeutic efficacy while minimizing unnecessary toxicity [1][2].
